BeWeld Medical

growth-positive

BeWeld Medical has signed a strategic investment agreement with Boston Scientific, a global medical technology leader. The agreement will enable BeWeld to further test and refine its innovative technology for automating the manufacturing processes of implanted medical devices. BeWeld was founded in 2021 by the MEDX Xelerator based on intellectual property developed by Professor Daniel Cohn and Abeer Khalaialh at the Hebrew University in Jerusalem. The company is led by CEO Asaf Gordon and CTO Ms. Khalaialh.

growth-positive

MEDX Xelerator, in cooperation with the Innovation Authority of Israel, has founded three new start-up companies. The companies will benefit from financing and support services offered by MEDX Xelerator to expedite technology development. The three companies are VeinWay, EyeMed, and BeWeld. MEDX Xelerator works closely with hospitals and multinational companies to identify and fill unmet clinical needs through innovation. The company has achieved significant milestones, including collaborations with CBG and West Pharmaceutical Services, and the establishment of a special program for entrepreneurs developing cardiovascular medical devices.